The reduction in price target by a major financial institution like JP Morgan, despite maintaining a Neutral rating, could lead to a negative short-term sentiment among investors. This adjustment reflects a slightly less optimistic outlook on AnaptysBio's stock, potentially due to revised expectations on the company's future performance.